$FLZH

MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media

MindWave Innovations (subsidiary of Apimeds Pharmaceuticals, NYSE: APUS) signed a 12-month agreement with Flash Sports & Media (OTC: FLZH) to build and operate FlashChain, a blockchain for tracking digital broadcasting rights and ticket inventory. MindWave will receive FLZH shares and 20% of FLASH TOKEN supply as consideration.

Original reporting
Published Sep 29, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 5:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$FLZH
Bullish
high confidence
Mentioned
$FLZH
Relevance
6/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$FLZHBullishLow
01

Why it matters

The deal provides FLZH with a dedicated blockchain subnet, validator operation, and a token allocation, potentially enhancing its product offering and market perception.

02

Market read

A new blockchain partnership that could affect FLZH's share price and token market dynamics.

03

What to watch

Potential regulatory scrutiny of token issuance and the lack of disclosed financial terms.

Relevance 6/10Novelty 6/10Timing: effective immediately upon signing

Background

MindWave Innovations, a subsidiary of APUS, is expanding its blockchain services into sports ticketing through a new agreement with FLZH.

Company-level read

Ticker impact

$FLZHBullishHigh confidence
Context

Flash Sports & Media Holdings (FLZH) signed a 12‑month blockchain services agreement with MindWave Innovations, receiving shares and token allocation.

Expected impact

likely upward pressure as market prices in the new blockchain contract and token issuance.

Evidence & confidence

The agreement provides FLZH with technology infrastructure, validator services, and a 20% token allocation, representing a material strategic development.

Market effects

May signal growing adoption of blockchain solutions in sports ticketing and media distribution.

Primarily U.S. OTC market where FLZH trades.

Limited to niche blockchain and sports media sectors.

Counterpoint

The partnership's impact could be muted if the technology fails to scale or token value remains low.

Key entities

  • MindWave Innovations Inc.

    Subsidiary of APUS providing blockchain infrastructure.

  • Flash Sports & Media Holdings, Inc.

    OTC‑listed firm operating streaming and ticketing platforms.

Related articles

$FLZHMed

Flash (NASDAQ: FLZH) Reports $266 million in Total Assets and $2.4 million in Cash at Second Quarter-End; $3.4 million of LPL Season 6 Fees Billed in Advance

Flash Sports & Media Holdings, Inc. (FLZH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Flash (NASDAQ: FLZH) Reports $266 million in Total Assets and $2.4 million in Cash at Second Quarter-End; $3.4 million of LPL Season 6 Fees Billed in Advance Second Quarter and First Half 2026 Highlights ● Total stockholders’ equity of $191.9 million at June 30, 2026

$COINMed

Citi Just Connected Its $6 Trillion Payment Network to Stablecoin Rails — and Every eCommerce Platform Is Now a Potential On-Ramp

Citi and Coinbase expanded their partnership to integrate stablecoin payments into Citi's $6 trillion payment network. Merchants can accept stablecoins via Spring by Citi, with Coinbase handling conversions. Citi absorbs conversion risk, and merchants receive fiat. Coinbase offers a 3.75% yield on stablecoin balances, not FDIC-insured. The collaboration aims to streamline stablecoin adoption for institutional clients, leveraging existing regulatory frameworks.

$GKOSMedAI 8/10

Glaukos' Epioxa Shows Durable Benefits At Three Years In Keratoconus Study

Glaukos (GKOS) reported positive three-year data from a Phase 3 extension study of Epioxa, its corneal cross-linking therapy for keratoconus. The study showed durable efficacy and a favorable safety profile, with treated eyes showing sustained improvement in corneal curvature and visual acuity. GKOS reported a narrowed net loss and 50% sales growth in Q2 2026, with 2026 net sales guidance of $680M-$700M. The stock is up 6.55% on the day.

$ADXNMedAI 8/10

Addex Therapeutics: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia

Addex Therapeutics (ADXN) announced its spin-out, Neurosterix, completed Phase 1 trials for NTX-253, a schizophrenia treatment. Neurosterix plans to advance NTX-253 to Phase 2. Addex holds a 20% stake in Neurosterix, which raised $65M in Series A funding. NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, showing promising preclinical results.